Literature DB >> 15155630

Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.

Nehal Mohamed1, Juan Li, Claudia S Ferreira, Stephen F Little, Arthur M Friedlander, George L Spitalny, Leslie S Casey.   

Abstract

We investigated the ability of using monoclonal antibodies (MAbs) against anthrax protective antigen (PA), an anthrax exotoxin component, to modulate exotoxin cytotoxic activity on target macrophage cell lines. Anthrax PA plays a critical role in the pathogenesis of Bacillus anthracis infection. PA is the cell-binding component of the two anthrax exotoxins: lethal toxin (LeTx) and edema toxin. Several MAbs that bind the PA component of LeTx are known to neutralize LeTx-mediated killing of target macrophages. Here we describe for the first time an overlooked population of anti-PA MAbs that, in contrast, function to increase the potency of LeTx against murine macrophage cell lines. The results support a possible mechanism of enhancement: binding of MAb to PA on the macrophage cell surface stabilizes the PA by interaction of MAb with macrophage Fcgamma receptors. This results in an increase in the amount of PA bound to the cell surface, which in turn leads to an enhancement in cell killing, most likely due to increased internalization of LF. Blocking of PA-receptor binding eliminates enhancement by MAb, demonstrating the importance of this step for the observed enhancement. The additional significance of these results is that, at least in mice, immunization with PA appears to elicit a poly-clonal response that has a significant prevalence of MAbs that enhance LeTx-mediated killing in macrophages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155630      PMCID: PMC415670          DOI: 10.1128/IAI.72.6.3276-3283.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.

Authors:  B D Wines; M S Powell; P W Parren; N Barnes; P M Hogarth
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

2.  Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization.

Authors:  Shihui Liu; Stephen H Leppla
Journal:  J Biol Chem       Date:  2002-12-04       Impact factor: 5.157

3.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

4.  Production and purification of anthrax toxin.

Authors:  S H Leppla
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

5.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

6.  Anthrax lethal toxin induces human endothelial cell apoptosis.

Authors:  James E Kirby
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis.

Authors:  F A BEALL; M J TAYLOR; C B THORNE
Journal:  J Bacteriol       Date:  1962-06       Impact factor: 3.490

8.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

9.  Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro.

Authors:  M Gröger; G Sarmay; E Fiebiger; K Wolff; P Petzelbauer
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

10.  MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells.

Authors:  X Zhu; G Meng; B L Dickinson; X Li; E Mizoguchi; L Miao; Y Wang; C Robert; B Wu; P D Smith; W I Lencer; R S Blumberg
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

View more
  37 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

3.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.

Authors:  Johanna Rivera; Antonio Nakouzi; Nareen Abboud; Ekaterina Revskaya; David Goldman; R John Collier; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.

Authors:  Kristina K Peachman; Mangala Rao; Carl R Alving; Robert Burge; Stephen H Leppla; Venigalla B Rao; Gary R Matyas
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.

Authors:  Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2009-07-05       Impact factor: 5.857

7.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

8.  Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Authors:  Kenneth Smith; Sherry R Crowe; Lori Garman; Carla J Guthridge; Jennifer J Muther; Emily McKee; Nai-Ying Zheng; A Darise Farris; Joel M Guthridge; Patrick C Wilson; Judith A James
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

9.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

10.  Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.

Authors:  Emmanuelle Laffly; Ludivine Danjou; Florence Condemine; Dominique Vidal; Emmanuel Drouet; Marie-Paule Lefranc; Chantal Bottex; Philippe Thullier
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.